Hanall Biopharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Hanall Biopharma is a South Korean pharmaceutical company that develops and supplies prescription medicines and biopharmaceutical treatments to patients and healthcare providers.
It is listed on KOSPI, Korea's main stock exchange. The filing's table of contents indicates the business spans both a domestic pharmaceutical operation and consolidated subsidiaries, suggesting a multi-entity corporate structure, though the filing text provided does not detail a single dominant product line.
Summary is AI-generated and may contain errors · figures from DART filings
Hanall Biopharma in five facts
What does Hanall Biopharma do?
Hanall Biopharma is a South Korean pharmaceutical company that develops and supplies prescription medicines and biopharmaceutical treatments to patients and healthcare providers.
Where is Hanall Biopharma listed and in which sector?
Hanall Biopharma (Korean name: 한올바이오파마) trades under KRX code 009420 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Hanall Biopharma?
Its market capitalisation was US$1.6B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Hanall Biopharma's latest annual revenue and operating profit?
For fiscal year 2025, Hanall Biopharma reported revenue of US$117.1M, an operating loss of US$691.2K and a net loss of US$4.2M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 11.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 6
- Operating results (consolidated) (preliminary) (fair disclosure)
Hanall Biopharma filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$30.7M (+8.8% year on year), operating profit of US$3.88M (+388.5% year on year) and a net loss of US$13.3M (from a profit a year earlier).
Earnings · Jul 29 - Treasury share disposal: results reportTreasury Shares · May 6
- Operating results (consolidated) (preliminary) (fair disclosure)
Hanall Biopharma filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$26.9M (+10.7% year on year), operating profit of US$564K (from a loss a year earlier) and net income of US$185K (from a loss a year earlier).
Earnings · Apr 29 - Material event report (treasury share disposal)
Hanall Biopharma disclosed a plan to sell treasury shares worth US$1.22M, about 0.1% of its market value.
Treasury Shares · Apr 29 - Treasury share disposal: results reportTreasury Shares · Mar 11
- Material event report (treasury share disposal)
Hanall Biopharma disclosed a plan to sell treasury shares worth US$128K, about 0.0% of its market value.
Treasury Shares · Mar 9 - Treasury share disposal: results reportTreasury Shares · Mar 3
- Material event report (treasury share disposal)
Hanall Biopharma disclosed a plan to sell treasury shares worth US$75.5K, about 0.0% of its market value.
Treasury Shares · Feb 25 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 21
- Operating results (consolidated) (preliminary) (fair disclosure)Earnings · Jan 21